宏輝集團(00183.HK)擬出資2000萬元成立合夥企業
格隆匯12月23日丨宏輝集團(00183.HK)發佈公吿,2021年12月23日,瑞智(集團的全資附屬公司)簽署出資協議,內容有關瑞智向合夥企業出資人民幣2000萬元。瑞智(作為合夥企業的有限合夥人)與普通合夥人(作為合夥企業的普通合夥人)將訂立合夥協議以成立合夥企業。
合夥企業為於中國成立的有限合夥企業,主要通過股權投資或準股權投資的方式對新興產業領域內的子基金及企業進行投資。根據有限合夥協議,合夥企業的目標規模將為人民幣15億元(相當於約18億港元),及瑞智的總出資額為人民幣2000萬元(相當於約2440萬港元)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.